A Phase 1 Open-Label Study of the Safety Tolerability and Efficacy of KPT-9274 A Dual Inhibitor of PAK4 and NAMPT in Patients with Advanced Solid Malignancies or Non-Hodgkin's Lymphoma (PANAMA)
Brief description of study
if you are newly diagnosed with non-Hodgkin's lymphoma or advanced solid malignancies, you may qualify to participate in a clinical trial. The main goal of this phase I study is to evaluate the safety, tolerability, and efficacy of an investigational drug, oral KPT-9274 for the treatment of your diseases.
Clinical Study Identifier: s16-00464
ClinicalTrials.gov Identifier: NCT02702492
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
